Exhaled breath of volatile organic compounds for IBD diagnosis and management

Exhaled breath analysis of VOCs using GC-MS and SIFT-MS offers a non-invasive, efficient, and cost-effective method to diagnose and monitor IBD, overcoming the limitations of current invasive tests.

WO2025245006A1PCT designated stage Publication Date: 2025-11-27THE CLEVELAND CLINIC FOUND
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/030003
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-20
Filing Date
2025-05-19
Publication Date
2025-11-27

AI Technical Summary

Technical Problem

Current diagnostic strategies for inflammatory bowel disease (IBD) rely on invasive testing methods like stool and serum evaluations, which have low patient uptake and sensitivity, leading to delayed diagnosis and treatment.

Method used

A non-invasive method using exhaled breath analysis to detect volatile organic compounds (VOCs) such as 2-propanol, ethane, heptanal, hydrogen sulfide, methyl acetate, octanoic acid, phenol, and propanoic acid to diagnose and monitor IBD, employing techniques like Gas Chromatography-Mass Spectrometry (GC-MS) and Selected Ion Flow Tube Mass Spectrometry (SIFT-MS) to quantify VOC levels.

Benefits of technology

Provides a high-uptake, cost-effective, and non-invasive diagnostic tool for IBD that can differentiate between IBD patients and healthy individuals, monitor treatment efficacy, and reduce the need for invasive procedures like colonoscopy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000014_0001
    Figure IMGF000014_0001
  • Figure IMGF000015_0001
    Figure IMGF000015_0001
  • Figure IMGF000016_0001
    Figure IMGF000016_0001
Patent Text Reader

Abstract

Provided herein arc systems and methods for testing exhaled breath from a subject (e.g., suspected of having inflammatory bowel disease, IBD) to determine the level of at least one volatile organic compound (e.g., 1 or 5 or 8 compounds). In certain embodiments, one receives test results, such as an elevated or decreased level of a particular volatile organic compound, and this is used to determine if a subject has IBD or needs treatment with an IBD treating agent. In other embodiments, the subject is treated with an IBD treating agent, and optionally tested again to monitor treatment (e.g., tested over days, weeks, or months). In other embodiments, the subject is determined to have moderate or severe IBD, or mild or no IBD.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • System and method for differential diagnosis of diseases

    US20190271685A1

  • Treatment of a disease of the gastrointestinal tract with a TNF inhibitor

    US20190343425A1

  • Compositions and methods for monitoring progression and regression of disease in patients in response to therapy

    US20200245926A1